DOI: 10.1093/jjco/hyad103 ISSN:
Adjuvant and neoadjuvant chemotherapy for biliary tract cancer: a review of randomized controlled trials
Kohei Nakachi, Naoto Gotohda, Etsuro Hatano, Satoshi Nara, Shinichiro Takahashi, Yasuyuki Kawamoto, Makoto Ueno- Cancer Research
- Radiology, Nuclear Medicine and imaging
- Oncology
- General Medicine
Abstract
The first randomized controlled trial of adjuvant chemotherapy for biliary tract cancer was reported in 2002. Since then, studies have continued, with efficacy reported for capecitabine in 2018 and S-1 in 2023. Oral fluoropyrimidines have become established as the standard of care. This article reviews the evidence from the randomized controlled trials reported to date and those that are ongoing or from which results have not yet been reported.